stockportfolio.pro
Recursion Pharmaceuticals, Inc. (RXRX)
Healthcare · Biotechnology · NasdaqGS
Recursion Pharmaceuticals, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.32M | $3.96M | $10.18M | $39.68M | $43.88M | $58.49M | $74.26M |
| Gross profit | — | — | — | $-8.59M | $1.29M | $13.25M | $3.30M |
| Net income | $-61.88M | $-87.01M | $-186.48M | $-239.48M | $-328.07M | $-463.66M | $-644.76M |
| Net margin | -2668.3% | -2196.0% | -1832.2% | -603.5% | -747.7% | -792.7% | -868.3% |
Source: Recursion Pharmaceuticals, Inc. SEC filings (10-K).
Explore 7 years of Recursion Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RXRX in your portfolio →
Recursion Pharmaceuticals, Inc. financial history by metric
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals, Inc. — frequently asked questions
What is Recursion Pharmaceuticals, Inc.'s revenue?
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $74.26M for fiscal year 2025, up 27.0% from the prior year, according to its SEC filings.
Is Recursion Pharmaceuticals, Inc. profitable?
No — RXRX reported a net loss of $-644.76M in fiscal 2025.
What is RXRX's P/E ratio?
Recursion Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Recursion Pharmaceuticals, Inc. growing?
RXRX's revenue grew at roughly 79.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Recursion Pharmaceuticals, Inc. have?
As of fiscal year 2025, RXRX carried roughly $18.66M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Recursion Pharmaceuticals, Inc.'s gross margin?
RXRX's gross margin was 4.4% in fiscal 2025 — gross profit of $3.30M on revenue of $74.26M.
What is Recursion Pharmaceuticals, Inc.'s market cap?
Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalization of about $1.60B, based on the latest data in our nightly-refreshed cache.
When does Recursion Pharmaceuticals, Inc.'s fiscal year end?
RXRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Recursion Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.